Real-time abdominal pain - daily life trigger associations in IBS: a multicenter Experience Sampling Method Study: GI Signals

Motility prospective cohort · n=360 · Oct 6, 2026 · Clin Gastro Hep · IF 16.2

Real-time abdominal pain - daily life trigger associations in IBS: a multicenter Experience Sampling Method Study.

Basic scienceIBSbasic sciencebiomarker

Clinical takeawayConsider discussing the bidirectional links between daily life triggers (positive/negative affect, environmental comfort, eating) and abdominal pain with IBS patients, particularly those with varying severity and comorbidities, to support personalized care.

What it foundHigher positive affect and environmental comfort were associated with lower pain (b=-0.23, p<0.001 and b=-0.18, p<0.01), while negative affect and eating were associated with higher pain (b=0.34 and b=0.13; both p<0.001).

ContextThis study provides real-time insights into the dynamic interplay between abdominal pain and daily life triggers in Rome IV IBS patients, emphasizing the role of IBS severity and comorbidities in symptom patterns.

Emergingsuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Management of Irritable Bowel Syndrome', 2021

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Diagnosis: use a positive diagnostic strategy based on Rome IV criteria rather than a strategy of exclusion (strong for cost-effectiveness, high quality; consensus for time-to-therapy), and categorize by IBS subtype (consensus). In patients with IBS and diarrhea symptoms: check celiac serology (strong, moderate) and, in those WITHOUT alarm features, fecal calprotectin (or fecal lactoferrin) plus CRP to rule out IBD (strong; moderate quality for CRP/calprotectin, very low for lactoferrin). Recommend AGAINST routine stool testing for enteric pathogens (conditional, low) and AGAINST routine colonoscopy in patients younger than 45 without warning signs (conditional, low). Anorectal physiology testing only when symptoms suggest a pelvic floor disorder and/or for refractory constipation not responding to standard medical therapy (consensus). Treatment, all subtypes: soluble, not insoluble, fiber (strong, moderate); a LIMITED trial of a low-FODMAP diet (conditional, very low); gut-directed psychotherapies for global symptoms (conditional, very low); TCAs for global symptoms (strong, moderate); peppermint suggested (conditional, low); antispasmodics for abdominal pain (conditional, low); AGAINST probiotics (conditional, very low), AGAINST fecal transplant (strong, very low). IBS-C: chloride channel activators (strong, moderate) and guanylate cyclase activators (strong, high); AGAINST PEG products for global IBS-C symptoms (conditional, low); tegaserod reserved for women younger than 65 with ≤1 cardiovascular risk factor who have not adequately responded to secretagogues (strong/conditional, low). IBS-D: rifaximin (strong, moderate); alosetron only for women with severe IBS-D who have failed conventional therapy (conditional, low); mixed opioid agonists/antagonists, i.e. eluxadoline (conditional, moderate); AGAINST bile acid sequestrants (conditional, very low).

American College of Gastroenterology, 'ACG Clinical Guideline: Management of Irritable Bowel Syndrome', 2021 · reviewed 2026-07-21 ↗

Bosman M … ESM study group · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink